Triple vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease

Conclusions
Triple therapy with prostanoids is safe and effective for patients with PAH-CHD, improving FC, 6MWTD and NT-proBNP levels over 2 years. The treatment is particularly beneficial for patients with pre-tricuspid defects and non-Eisenmenger PAH-CHD.

Source: Heart - February 12, 2024 Category: Cardiology Authors: Luna-Lopez, R., Segura de la Cal, T., Sarnago Cebada, F., Martin de Miguel, I., Hinojosa, W., Cruz-Utrilla, A., Velazquez, M. T., Delgado, J. F., Mendoza, A., Arribas Ynsaurriaga, F., Escribano-Subias, P. Tags: Congenital heart disease Source Type: research